+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07607678

Testing How Different Doses of BI 3819026 Alone and with Ezabenlimab Are Tolerated in Adults With Advanced or Metastatic Solid Cancers

Led by Boehringer Ingelheim · Updated on 2026-09-29

60

Participants Needed

9

Research Sites

123 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating different doses of the study drug BI 3819026 alone and in combination with ezabenlimab in adults with advanced or metastatic solid cancers. The study aims to find the highest dose of BI 3819026 that patients can tolerate safely. This is a phase 1 trial conducted by Boehringer Ingelheim to determine the maximum tolerated dose and recommended dose for expansion. Participants first receive a single treatment of BI 3819026 alone, followed by combination treatment with BI 3819026 and ezabenlimab. Dose escalation occurs in small groups starting at the lowest dose, increasing only if the previous dose is tolerated. Each participant remains on their assigned dose throughout the study, which can last up to two years as long as treatment is tolerated and the disease does not worsen. During the study, participants regularly visit the study site for monitoring. Doctors assess dose-limiting toxicities and adverse events, take blood samples, and image tumors to track treatment effects. The primary outcome is the occurrence of dose-limiting toxicities within the first 30 days, with additional safety and pharmacokinetic measurements collected throughout the treatment period.

CONDITIONS

Brief Title

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here